The role of cholesterol biosynthesis in metastatic and recurrent endometrial cancer
胆固醇生物合成在转移性和复发性子宫内膜癌中的作用
基本信息
- 批准号:10467152
- 负责人:
- 金额:$ 25.49万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-02-02 至 2022-08-31
- 项目状态:已结题
- 来源:
- 关键词:AbdomenAblationAdjuvantAnimal ModelCellsCholesterolDataDevelopmentDiagnosisDistant MetastasisEndometrial CarcinomaEstrogensExhibitsFDA approvedGene ExpressionGene TargetingGenesGenetically Engineered MouseHigh Fat DietHistologicHumanHysterectomyKnowledgeLungMalignant Female Reproductive System NeoplasmMediator of activation proteinMetastatic/RecurrentMitogensMolecular ProfilingMusMutant Strains MiceMutateMutationNeoplasm Circulating CellsNeoplasm MetastasisOperative Surgical ProceduresPTEN genePathway interactionsPatientsPreclinical TestingPrimary NeoplasmProgesteronePrognosisProto-Oncogene Proteins c-aktRecurrenceRecurrent tumorResolutionRoleSignal TransductionStagingTestingTherapeuticTumor Suppressor GenesUterusWomanWorkatorvastatinbasecancer cellcancer recurrencecholesterol biosynthesisexperimental studyhigh riskimprovedin vivoinnovationmTOR inhibitionmouse modelnovelnovel therapeuticsoverexpressionpre-clinicalpreventtranscriptometumortumor progressiontumorigenic
项目摘要
Endometrial cancer is the most common gynecologic malignancy, with an estimated 66,570 new cases in 2021.
Although early-stage and low grade endometrial cancer generally exhibits a favorable prognosis, metastatic
and recurrent endometrial cancer is incurable with currently available standard therapies for most women.
Therefore, there is an urgent obligation to explore the mechanism of tumor metastasis and recurrence to
further elucidate the progression of endometrial cancer. We have developed a genetically engineered mouse
model for metastatic and recurrent endometrial cancer that implicates coexistent Pten and Mig-6 mutations in
endometrial cancer. Pten mutation is not sufficient for distant metastasis, but mice with concurrent ablation of
Mig-6 and Pten develop distant metastasis. After hysterectomy at stage I of endometrial cancer in mutant mice
with deficiency of Pten and Mig-6, the double mutant mice developed recurrence of endometrial cancer in the
abdomen and lung. Our preliminary results show that the expression of genes related to cholesterol
biosynthesis pathway was significantly increased in the mutant mice. Based upon these results, we
hypothesize that MIG-6 suppresses metastasis and recurrence in endometrial cancer with PTEN
mutation by inhibiting cholesterol biosynthesis. Our Specific Aims are directed at understanding: 1) the
tumorigenic effects of MIG-6 loss in recurrence of endometrial cancer with PTEN mutation; 2) the molecular
signature of primary tumor, circulating tumor cells, and recurrent tumor in the mutant mice; and 3) the ability of
statins to prevent recurrence in endometrial cancer. There is strong innovation in the novelty of our hypotheses
and cutting-edge technical approaches. In particular, we will employ the first preclinical animal model that
closely resembles human endometrial cancer with distant metastasis and recurrence.
子宫内膜癌是最常见的妇科恶性肿瘤,2021年估计有66,570例新病例。
尽管早期和低级别的子宫内膜癌通常表现出良好的预后,
而对于大多数女性来说,目前可用的标准疗法是无法治愈复发的子宫内膜癌的。
因此,探讨肿瘤转移复发的机制迫在眉睫。
进一步阐明子宫内膜癌的进展。我们已经开发出一种基因工程小鼠
Pten和Mig-6基因突变共存的子宫内膜癌转移和复发模型
子宫内膜癌。PTEN突变不足以导致远处转移,但同时消融的小鼠
MiG-6和Pten发生远处转移。突变小鼠子宫内膜癌I期子宫切除术后
在缺乏Pten和Mig-6的情况下,双突变小鼠出现子宫内膜癌复发
腹部和肺部。我们的初步结果表明,与胆固醇相关的基因表达
突变小鼠的生物合成途径显著增加。基于这些结果,我们
假设MIG-6抑制PTEN治疗子宫内膜癌的转移和复发
通过抑制胆固醇的生物合成而发生突变。我们的具体目标是了解:1)
MIG-6缺失在PTEN突变子宫内膜癌复发中的致瘤作用
突变小鼠的原发肿瘤、循环肿瘤细胞和复发肿瘤的特征;以及3)
他汀类药物预防子宫内膜癌复发。我们假设的新颖性有很强的创新性
和尖端的技术方法。特别是,我们将采用第一个临床前动物模型
与人类子宫内膜癌相似,有远处转移和复发。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jae-Wook Jeong其他文献
Jae-Wook Jeong的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jae-Wook Jeong', 18)}}的其他基金
The role of cholesterol biosynthesis in metastatic and recurrent endometrialcancer
胆固醇生物合成在转移性和复发性子宫内膜癌中的作用
- 批准号:
10560609 - 财政年份:2022
- 资助金额:
$ 25.49万 - 项目类别:
Molecular mechanisms of endometrial progesterone resistance
子宫内膜黄体酮抵抗的分子机制
- 批准号:
10618181 - 财政年份:2022
- 资助金额:
$ 25.49万 - 项目类别:
Development of anti-inflammatory nanodrug for endometriosis treatment
开发治疗子宫内膜异位症的抗炎纳米药物
- 批准号:
10709492 - 财政年份:2022
- 资助金额:
$ 25.49万 - 项目类别:
The role of cholesterol biosynthesis in metastatic and recurrent endometrialcancer
胆固醇生物合成在转移性和复发性子宫内膜癌中的作用
- 批准号:
10661912 - 财政年份:2022
- 资助金额:
$ 25.49万 - 项目类别:
Epigenetic regulation of receptive endometrium
容受性子宫内膜的表观遗传调控
- 批准号:
10674101 - 财政年份:2022
- 资助金额:
$ 25.49万 - 项目类别:
Epigenetic regulation of receptive endometrium
容受性子宫内膜的表观遗传调控
- 批准号:
10551346 - 财政年份:2022
- 资助金额:
$ 25.49万 - 项目类别:
Molecular mechanisms of endometrial progesterone resistance
子宫内膜黄体酮抵抗的分子机制
- 批准号:
10662676 - 财政年份:2022
- 资助金额:
$ 25.49万 - 项目类别:
Epigenetic regulation of receptive endometrium
容受性子宫内膜的表观遗传调控
- 批准号:
10390408 - 财政年份:2021
- 资助金额:
$ 25.49万 - 项目类别:
SIRT1 as a Therapeutic Target in Endometriosis
SIRT1 作为子宫内膜异位症的治疗靶点
- 批准号:
10309093 - 财政年份:2021
- 资助金额:
$ 25.49万 - 项目类别:
Epigenetic regulation of receptive endometrium
容受性子宫内膜的表观遗传调控
- 批准号:
10231662 - 财政年份:2021
- 资助金额:
$ 25.49万 - 项目类别:
相似海外基金
Targeted ablation of cerebral atherosclerosis using supramolecular self-assembly
利用超分子自组装靶向消融脑动脉粥样硬化
- 批准号:
24K21101 - 财政年份:2024
- 资助金额:
$ 25.49万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
心房細動に対するPulsed Field Ablationの組織創傷治癒過程を明らかにする網羅的研究
阐明房颤脉冲场消融组织伤口愈合过程的综合研究
- 批准号:
24K11201 - 财政年份:2024
- 资助金额:
$ 25.49万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
遅延造影心臓MRIによる心房細動Ablation冷却効果の比較:28 vs. 31 mm Cryoballoon
使用延迟对比增强心脏 MRI 比较房颤消融冷却效果:28 毫米与 31 毫米 Cryoballoon
- 批准号:
24K11281 - 财政年份:2024
- 资助金额:
$ 25.49万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
InSPACE-VT_Development and Validation of Virtual Pace Mapping to Guide Catheter Ablation of Ventricular Tachycardia
InSPACE-VT_虚拟起搏测绘的开发和验证以指导室性心动过速导管消融
- 批准号:
EP/Z001145/1 - 财政年份:2024
- 资助金额:
$ 25.49万 - 项目类别:
Fellowship
CAREER: Heat Penetration Depth and Direction Control with Closed-Loop Device for Precision Ablation
职业:利用闭环装置控制热穿透深度和方向,实现精确烧蚀
- 批准号:
2338890 - 财政年份:2024
- 资助金额:
$ 25.49万 - 项目类别:
Continuing Grant
Collaborative Research: RUI: Frontal Ablation Processes on Lake-terminating Glaciers and their Role in Glacier Change
合作研究:RUI:湖终止冰川的锋面消融过程及其在冰川变化中的作用
- 批准号:
2334777 - 财政年份:2024
- 资助金额:
$ 25.49万 - 项目类别:
Continuing Grant
Collaborative Research: RUI: Frontal Ablation Processes on Lake-terminating Glaciers and their Role in Glacier Change
合作研究:RUI:湖终止冰川的锋面消融过程及其在冰川变化中的作用
- 批准号:
2334775 - 财政年份:2024
- 资助金额:
$ 25.49万 - 项目类别:
Continuing Grant
Collaborative Research: RUI: Frontal Ablation Processes on Lake-terminating Glaciers and their Role in Glacier Change
合作研究:RUI:湖终止冰川的锋面消融过程及其在冰川变化中的作用
- 批准号:
2334776 - 财政年份:2024
- 资助金额:
$ 25.49万 - 项目类别:
Continuing Grant
Cryo laser-ablation system (157+193nm) with 'triple-quad' plasma mass spectrometer, Cryo-LA-ICPMS/MS
带有“三重四极杆”等离子体质谱仪、Cryo-LA-ICPMS/MS 的冷冻激光烧蚀系统 (157 193nm)
- 批准号:
515081333 - 财政年份:2023
- 资助金额:
$ 25.49万 - 项目类别:
Major Research Instrumentation
MRI: Acquisition of a Laser Ablation - Inductively Coupled Plasma - Triple Quadrupole - Mass Spectrometer (LA-ICP-QQQ-MS) System For Research and Education
MRI:获取用于研究和教育的激光烧蚀 - 电感耦合等离子体 - 三重四极杆 - 质谱仪 (LA-ICP-MS/MS) 系统
- 批准号:
2320040 - 财政年份:2023
- 资助金额:
$ 25.49万 - 项目类别:
Standard Grant














{{item.name}}会员




